Marksans Pharma Limited · NSE:MARKSANS

Marksans Pharma — Investor Presentation (January 2014)

43 slides from Marksans Pharma's investor presentation, January 2014

  1. Slide 1: Investor Presentation

    Investor Presentation Strictly Private & Confidential

  2. Slide 2: Company Overview

    g Marksans Pharma Ltd. Company Overview

  3. Slide 3: Marksans Pharma Limited (MPL)

    Marksans Pharma Limited (MPL)  Marksans straddles across key therapy areas and markets its products in both evolving and developed markets  Core competencies: Formulations manufacturing and marketing World Class CRAMS Services Manufacturing Facilities - Utilizing Low Cost Own Front Ends into Appro

  4. Slide 4: Historical Profit and Loss Account

    Historical Profit and Loss Account (Rs. In crores) FY2013 FY2013 Particulars (Standalone) (Consolidated) Sales 192.30 438.42 Other Income 4.17 4.40 Total Income 196.47 442.82 Cost of materials consumed 65.96 135.93 Purchases of Stock-in-Trade 27.55 104.78 Changes in inventories of finished goods, wo

  5. Slide 5: Historical Balance Sheet

    Historical Balance Sheet (Rs . In crores ) FY2013 FY2013 Particulars (Standalone) (Consolidated) EQUITY AND LIABILITIES Share capital 52.03 52.03 Res erves and s urplus 57.95 34.45 Minority Interes t - 6.99 Non-current liabilities Long-term borrowings 7.88 7.88 Deferred tax liabilities (Net) 2.22 2.

  6. Slide 6: Shareholding Pattern

    Shareholding Pattern Name of the Shareholder No. of shares % holding held Promoters 197307732 51.21 Foreign Institutional Investors 1117391 0.29 Body Corporate 28127426 7.3 Individuals & Others 158754655 41.2 Total 385307204 100 6

  7. Slide 7: The Promoters

    The Promoters  The Company was established by Mr. Mark Saldanha, a first generation entrepreneur, with the vision to develop a global pharmaceutical company.  MPL is rapidly progressing and expanding under his dynamic leadership. Mr. Saldanha has more than two decades of experience in production,

  8. Slide 8: State-of-the-Art Manufacturing Facilities

    State-of-the-Art Manufacturing Facilities  Marksans Goa Manufacturing Facility – one of the largest in Asia for soft gelatin capsules and tablets  Multi-purpose UK MHRA licenced facility at Southport UK Accredited by Accredited & Approved by 8

  9. Slide 9: Manufacturing Facilities–Goa

    Manufacturing Facilities–Goa  International Standards adhering to Stringent Quality Norms  World Class Manufacturing Capabilities catering to Formulations  Key Features:  18,000 sq. ft with Scalable Capacity  100% EOU  USFDA , UK MHRA, Australian TGA approved  One of the Largest Manufacturing

  10. Slide 10: Product Portfolio

    /O Product Portfolio g} Marksans Pharma tat

  11. Slide 11: Strengths

    Strengths World-Class Strong R&D, Manufacturing Low Cost Dossier Global Presence Facilities with Manufacturing Base Development Scalable Capacities Capabilities Tie Ups with Preferred Wider Product CRAMS for Market Leaders Outsourcing Partner Basket (OTC to Rx) US/Global Markets US FDA, UK Own Front

  12. Slide 12: Strategy & Growth Initiatives

    Strategy & Growth Initiatives 12

  13. Slide 13: Growth Strategy

    Growth Strategy MARKSANS PHARMA GROWTH STRATEGIES ORGANIC IN-ORGANIC GROWTH STRATEGY GROWTH STRATEGY 13

  14. Slide 14: Organic Growth Strategies

    ORGANIC GROWTH STRATEGIES Market Share Market Leveraged Customer Leveraged Growth Growth Growth Strengthen and expand Increasing ANDAs pipeline by New opportunity evaluation current core businesses increasing R&D Capabilities and development ( Formulations) Expand offshore market Creating options fo

  15. Slide 15: Inorganic Growth Strategies

    INORGANIC GROWTH STRATEGIES Acquisitions Strategic Alliance Initiatives already taken in this direction (Relonchem, UK; Bell Healthcare, UK & Out-licensing ANDAs to increase market Nova Pharmaceuticals, Australia) penetration Instantly added new brands, products and Combined competitive energies int

  16. Slide 16: Key Growth Drivers

    Key Growth Drivers  Rapid filing of ANDAs into the US, Europe & emerging markets.  Expand Contract Research and Manufacturing Services (CRAMS) in the Regulated Markets.  Acquisitions of growing, profitable pharmaceutical companies and/or products.  The company has entered into a share purchase a

  17. Slide 17: US Market – Post Patent Product Launch Strategy

    US Market – Post Patent Product Launch Strategy Technology Driven Niche Liquid Gel Market  This market is tapped by select players, thus providing differentiation in crowded generic market  Innovator Product  First to file the product in the US  Aiming for Day 1 launch after patent expiry in the

  18. Slide 18: Strategies for Targeting the Big Apple

    Strategies for Targeting the Big Apple  Target products coming off patent between 2013 and 2018  Tie ups with multinationals, generic companies and distributors for the distribution of our products in the US  Remain focused on the development of high-end Rx products for launch in the US  Commerc

  19. Slide 19: Emerging Markets – Current Status and Strategies

    Emerging Markets – Current Status and Strategies  Continue registration of products across geographies, with a focus on markets with high potential  Emerging markets - one of the major drivers and revenue earners for the company  Initiated launch of our own brand registration in emerging markets

  20. Slide 20: Subsidiaries

    20 Subsidiaries g Marksans Pharma tad.

  21. Slide 21: Marksans Pharma UK Ltd

    21 Marksans Pharma UK Ltd g} Marksans Pharma tat

  22. Slide 22: Introduction

    Introduction  Marksans Pharma UK Ltd. (“MPL UK”) is the UK-based wholly-owned subsidiary of Marksans Pharma Ltd.  Registered Office: Widnes, London  Mergers & Acquisitions:  Acquired UK-based pharma company, Hale Group, the parent company of Bell, Sons and Co (Druggists) in January 2008  Acquir

  23. Slide 23: Bell, Sons and Co (Druggists) Ltd.

    Bell, Sons and Co (Druggists) Ltd. 23

  24. Slide 24: Introduction

    Introduction  Bell is a well-established manufacturer of a broad range of OTC pharmaceuticals, approved by the UK MHRA  Human Resources: 106 people at the freehold licenced manufacturing site at Southport, Merseyside and 12 employees for sales administration, buying and technical support  Bell’s

  25. Slide 25: Products

    Products  The own label market now accounts Cough & for more than 45% of the Company’s Cold Remedies total turnover Antiseptics & Galenicals Disinfectants  Comprehensive UK customer base with excellent distribution between Product retail and wholesale sectors Basket Vitamins  Significant and well

  26. Slide 26: Export Trade

    Export Trade  Over 80 years of experience in the export market - a network of established distributors for overseas markets  The Company’s brand well-recognised and respected in overseas markets  Ensuring stability in terms of marketing & price maintenance by providing exclusive distribution righ

  27. Slide 27: Business Operations

    Business Operations  Supplier and manufacturing process  Supplier Approval: Key suppliers are audited covering quality and control procedures  Raw materials and packaging components are purchased only from approved suppliers Raw Materials Quality Chemical Released for & Packaging Control Analysis

  28. Slide 28: Business Operations (continued)

    …Business Operations  Product development  Product development undertaken by dedicated laboratory technicians in Widnes, Cheshire  16 products at various stages of development;  Research undertaken includes:  Developing products that complement its product range  Formulations for similar goods

  29. Slide 29: Key Attractions

    Key Attractions  Well established with Excellent Reputation in the UK and the Export Markets  Strong Presence in the Own-label Product Market (40% of turnover)  Potential to Introduce New Product Lines  Over 30% of Sales to Export Markets  Consistently Profitable with Good Prospects for Growth

  30. Slide 30: Upsides Envisaged

    Upsides Envisaged  The acquisition will provide Marksans an entry into the branded product category in Europe as Bell has a vast distribution network  Liquid formulations exports from India is poor. Bell manufacturing facilities can be used for the production of liquid dosages to supply Marksans’s

  31. Slide 31: Relonchem Ltd.

    34 Relonchem Ltd. g} Marksans Pharma tat

  32. Slide 32: Introduction

    Introduction  Set up in 2002 for licensing, marketing and supply of generic pharmaceutical products in the UK market  Product manufacturing done in India, ensuring a low cost of goods and a competitive position in the market  Distribution Partners: Major national distributors like AAH, Unichem an

  33. Slide 33: Product Registrations

    Product Registrations PRODUCT NAME PACK SIZE MAGRANTED Date Of Grant / Application Lansoprazole 15mg Caps 28 Lansoprazole 30mg Caps 28 Lipsore 5% Cream 1 a 20.10.2005 Lisinopril 2.5 mg Tablets 28 a 26.06.2004 Lisinopril 5 mg Tablets 28 a 26.06.2004 Lisinopril 10 mg Tablets 28 a 26.06.2004 Lisinopril

  34. Slide 34: Product Registrations (continued)

    …Product Registrations Date of Grant Product Name Pack Size Ma Granted /Application Lansoprazole 15mg Caps 28 28 Lansoprazole 30mg Caps 28 Lipsore 5% Cream 1 a 20.10.2005 Lisinopri l2.5mg Tablets 28 a 26.6.2004 Lisinopril 5mg Tablets 28 a 26.6.2004 Lisinopril 10mg Tablets 28 a 26.6.2004 Lisinopril 2

  35. Slide 35: Business Operations

    Business Operations  Sales and distribution  Sales and distribution is managed from Southport  Price structure is continually reviewed based on market intelligence  Excellent relationships with national distributors like AHH and Unichem.  Balance sold through regional wholesalers like Sigma and

  36. Slide 36: Key Attractions

    Key Attractions  Marketing and Distribution:  Strong sales and marketing expertise  Supplier to major national distributors, regional distributors and global generic players in the UK  Technical and Regulatory Expertise: Highly reputable track record for attaining MHRA approval for the manufactu

  37. Slide 37: Key Attractions (continued)

    …Key Attractions  People Resources: Excellent team, fully integrated with the Indian pharmaceutical market, optimising its management skills to source competitive services for the regulated markets of Europe  Strong Product Portfolio and Pipeline:  The profitability of Relonchem to date is clear

  38. Slide 38: Upsides Envisaged

    Upsides Envisaged  The UK is the second-largest generics market in the European Union, accounting for 26% of the market value.  UK generics market is one of the world’s largest in terms of both size and generic penetration.  The acquisition will provide Marksans immediate sales and marketing fron

  39. Slide 39: Nova Pharmaceuticals Australasia Pty. Ltd.

    Nova Pharmaceuticals Australasia Pty. Ltd. 39

  40. Slide 40: Introduction

    Introduction  Nova specialises in the research, development and marketing of high quality generic OTC pharmaceutical products to meet the ever-changing demands of the healthcare environment.  Nova endeavours to provide premium quality products at the best possible price.  All Nova products are in

  41. Slide 41: Key Attractions

    Key Attractions  Research-driven specialty pharmaceutical company  Prominent distributor: presence across leading pharmacies and major chain stores for distribution of generics and OTC products  Hold 30 MAs, and is one of the largest supplier of generics in Australasia  Robust operating margins

  42. Slide 42: Upsides Envisaged

    Upsides Envisaged  The acquisition will provide Marksans opportunity to differentiate from competitors  Expansion of presence & activities to New Zealand & Asia  Partnering for in- or out-licensing, collaborative R&D  Strategic product development alliances with key customers 42

  43. Slide 43: Thank You!

    43 Thank You! g} Marksans Pharma tat

Marksans Pharma — Investor Presentation (January 2014) on 6ix